124,583 results match your criteria Malignant Melanoma


Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.

J Neurosurg 2019 Feb 15:1-6. Epub 2019 Feb 15.

1Department of Neurosurgery, Yale New Haven Hospital, New Haven, Connecticut.

OBJECTIVEConcurrent use of anti-PD-1 therapies with stereotactic radiosurgery (SRS) have been shown to be beneficial for survival and local lesional control in melanoma patients with brain metastases. It is not known, however, if immunotherapy (IT) confers the same outcome advantage in lung cancer patients with brain metastases treated with SRS.METHODSThe authors retrospectively reviewed 85 non-small cell lung cancer (NSCLC) patients with brain metastases who were treated with SRS between January 2006 and December 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3171/2018.10.JNS181371DOI Listing
February 2019

UVB drives different stages of epigenome alterations during progression of skin cancer.

Cancer Lett 2019 Feb 13. Epub 2019 Feb 13.

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA. Electronic address:

Exposure to ultraviolet B (UVB) irradiation results in multitude of cellular responses including generation of reactive oxygen species and DNA damage and is responsible for non-melanoma skin cancers (NMSCs). Although genetic mutation is well documented, the epi-mutation, the alteration in epigenetics, remains elusive. In this study, we utilized CpG Methyl-seq to identify a genome-wide DNA CpG methylation, to profile the DNA methylation in UVB-irradiated SKH-1 mouse skin epidermis and non-melanoma skin papillomas at various stages. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2019.02.010DOI Listing
February 2019

Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells.

Cancer Lett 2019 Feb 13. Epub 2019 Feb 13.

Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA. Electronic address:

Inhibition of ubiquitin ligases with small molecule remains a very challenging task, given the lack of catalytic activity of the target and the requirement of disruption of its interactions with other proteins. Siah1/2, which are E3 ubiquitin ligases, are implicated in melanoma and prostate cancer and represent high-value drug targets. We utilized three independent screening approaches in our efforts to identify small-molecule Siah1/2 inhibitors: Affinity Selection-Mass Spectrometry, a protein thermal shift-based assay and an in silico based screen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2019.02.012DOI Listing
February 2019

The bidirectional crosstalk between metastatic uveal melanoma cells and hepatic stellate cells engenders an inflammatory microenvironment.

Exp Eye Res 2019 Feb 13. Epub 2019 Feb 13.

Inserm, Université de Rennes 1, UMR 1241, Nutrition, Métabolismes et Cancer (NuMeCan), Rennes, France; Département d'ophtalmologie, Faculté de Médecine, Université Laval, Québec, Canada; Centre Universitaire d'ophtalmologie-Recherche and Axe Médecine Régénératrice, Centre de Recherche du CHU de Québec-Université Laval, Québec, Canada; Centre de Recherche en Organogénèse Expérimentale de l'Université Laval/LOEX, Québec, Canada; Service d'ophtalmologie, CHU de Rennes, Rennes, France. Electronic address:

Uveal melanoma is the most common primary ocular neoplasm in adults. It is peculiar for its hematogenous dissemination and its high propensity to spread to the liver. Current treatments rarely prolong patient survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exer.2019.02.012DOI Listing
February 2019

Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer.

Med Sci Monit 2019 Feb 16;25:1275-1282. Epub 2019 Feb 16.

Department of Palliative Care, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).

BACKGROUND The aim of this study was to investigate the clinical correlation between sPD-1 (soluble programmed cell death-1) and PD-1 (programmed cell death-1) expression and cancer pain. MATERIAL AND METHODS sPD-1 content in peripheral blood was determined by enzyme-linked immunosorbent assay (ELISA). T cell surface-positive rate was determined by flow cytometry, and the correlation of clinical characteristics of patients with cancer pain was analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/MSM.912632DOI Listing
February 2019

Understanding Skin Screening Practices Among Children at Elevated Risk for Melanoma to Inform Interventions for Melanoma Prevention and Control.

J Cancer Educ 2019 Feb 15. Epub 2019 Feb 15.

Huntsman Cancer Institute, 2000 Circle of Hope, Rm 4509, Salt Lake City, UT, 84112, USA.

Melanoma is the deadliest form of skin cancer. Screening can aid in early disease detection, when treatment is more effective. Although there are currently no consensus guidelines regarding skin screening for pediatric populations with elevated familial risk for melanoma, at-risk children with the help of their parents and healthcare providers may implement skin self-exams. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13187-019-01489-3DOI Listing
February 2019

Current Treatment Options for Breast Cancer Brain Metastases.

Curr Treat Options Oncol 2019 Feb 15;20(3):19. Epub 2019 Feb 15.

Department of Medicine, Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Ave, S73, Cleveland, OH, 44195, USA.

Opinion Statement: In the past, the standard of care for treatment of BM was whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), and surgery. There has been a greater role for medical therapies in the last two decades due to the discovery of driver mutations and corresponding targeted therapies. These innovations have dramatically altered the approach to treating these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0618-5DOI Listing
February 2019

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.

Cancer Immunol Immunother 2019 Feb 15. Epub 2019 Feb 15.

CureVac AG, Tübingen, Germany.

CV9201 is an RNActive-based cancer immunotherapy encoding five non-small cell lung cancer-antigens: New York esophageal squamous cell carcinoma-1, melanoma antigen family C1/C2, survivin, and trophoblast glycoprotein. In a phase I/IIa dose-escalation trial, 46 patients with locally advanced (n = 7) or metastatic (n = 39) NSCLC and at least stable disease after first-line treatment received five intradermal CV9201 injections (400-1600 µg of mRNA). The primary objective of the trial was to assess safety. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02315-xDOI Listing
February 2019

Applying an innovative biodegradable self-assembly nanomicelles to deliver α-mangostin for improving anti-melanoma activity.

Cell Death Dis 2019 Feb 15;10(3):146. Epub 2019 Feb 15.

Department of Neurosurgery and Institute of Neurosurgery, State Key Lab of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, PR China.

α-Mangostin (αM), a traditional natural product with promising application of treating a series of diseases, was limited use in clinical due to its hydrophobicity. Herein, MPEG-PCL nanomicelles were used to embed the αM for resolving hydrophobicity and improving the anti-melanoma effect of the αM. The anti-melanoma activity and potential mechanisms of biodegradable αM/MPEG-PCL nanomicelles were investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41419-019-1323-9DOI Listing
February 2019

Ras-ERK1/2 signaling promotes the development of uveal melanoma by downregulating H3K14ac.

J Cell Physiol 2019 Feb 15. Epub 2019 Feb 15.

Department of Vascular Surgery, China-Japan Union Hospital of Jilin University, Changchun, China.

Ras-extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) signaling has been proposed as the crucial regulators in the development of various cancers. Histone acetylation at H3 lysine 14 (H3K14ac) is closely associated with gene expression and DNA damage. However, whether H3K14ac participates in mediating Ras-ERK1/2-induced cell proliferation and migration in uveal melanoma cells remains unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.28259DOI Listing
February 2019

Ras-PI3K-AKT signaling promotes the occurrence and development of uveal melanoma by downregulating H3K56ac expression.

J Cell Physiol 2019 Feb 15. Epub 2019 Feb 15.

Department of Vascular Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.

Background: Uveal melanoma (UM) is an intraocular malignant tumor characterized by rapid progression and recurrence. The current conventional treatments are unsatisfactory. Histone acetylation at H3 lysine 56 (H3K56ac) has been reported to be a tumor suppressor in breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.28261DOI Listing
February 2019

Bacterial Mix Enhances Immunotherapy Response.

Authors:

Cancer Discov 2019 Feb 15. Epub 2019 Feb 15.

Researchers have isolated a mix of 11 strains of bacteria that increase the effectiveness of checkpoint inhibitors in mice. The bacteria boosted IFNγ+ CD8+ T-cell counts and enhanced anti-PD-1 and anti-CTLA4 treatments in mice implanted with colon cancer or melanoma cells, findings that could have implications for patient care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-NB2019-020DOI Listing
February 2019

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

Clin Cancer Res 2019 Feb 15. Epub 2019 Feb 15.

Medical Oncology, University of Colorado Anschutz Medical Campus.

Purpose: IDO1 induces immune suppression in T cells through L-tryptophan (Trp) depletion and kyneurinine (Kyn) accumulation in the local tumor microenvironment, suppressing effector T-cells and hyperactivating Tregs. Navoximod is an investigational small molecule inhibitor of IDO1. This Phase I study evaluated safety, tolerability, PK and PD of navoximod in combination with atezolizumab, a PD-L1 inhibitor, in patients with advanced cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-2740DOI Listing
February 2019

Patient preferences on the use of technology in cancer surveillance after curative surgery: A cross-sectional analysis.

Surgery 2019 Feb 12. Epub 2019 Feb 12.

Department of Surgery, The Ohio State University Wexner Medical Center, Columbus. Electronic address:

Background: Advances in communication technology have enabled new methods of delivering test results to cancer survivors. We sought to determine patient preferences regarding the use of newer technology in delivering test results during cancer surveillance.

Methods: A single institutional, cross-sectional analysis of the preferences of adult cancer survivors regarding the means (secure digital communication versus phone call or office visit) to receive surveillance test results was undertaken. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.surg.2018.12.021DOI Listing
February 2019

Innate Immune Modulation by GM-CSF and IL-3 in Health and Disease.

Int J Mol Sci 2019 Feb 15;20(4). Epub 2019 Feb 15.

Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, 80131 Naples, Italy.

Granulocyte-macrophage colony-stimulating factor (GM-CSF) and inteleukin-3 (IL-3) have long been known as mediators of emergency myelopoiesis, but recent evidence has highlighted their critical role in modulating innate immune effector functions in mice and humans. This new wealth of knowledge has uncovered novel aspects of the pathogenesis of a range of disorders, including infectious, neoplastic, autoimmune, allergic and cardiovascular diseases. Consequently, GM-CSF and IL-3 are now being investigated as therapeutic targets for some of these disorders, and some phase I/II clinical trials are already showing promising results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20040834DOI Listing
February 2019

Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles.

Cancers (Basel) 2019 Jan 30;11(2). Epub 2019 Jan 30.

School of Medical and Health Sciences, Edith Cowan University, Perth, WA 6027, Australia.

Cutaneous melanoma circulating tumour cells (CTCs) are phenotypically and molecularly heterogeneous. We profiled the gene expression of CTC subpopulations immunomagnetic-captured by targeting either the melanoma-associated marker, MCSP, or the melanoma-initiating marker, ABCB5. Firstly, the expression of a subset of melanoma genes was investigated by RT-PCR in MCSP-enriched and ABCB5-enriched CTCs isolated from a total of 59 blood draws from 39 melanoma cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020157DOI Listing
January 2019

Melanoma Registry Underreporting in the Veterans Health Administration.

Fed Pract 2016 Aug;33(Suppl 5):55S-59S

is a physician, and is the cancer care program manager, both at VA Puget Sound Health Care System. is the VISN 20 data manager for the Store and Forward Teledermatology Program. Dr. Raugi is a professor of dermatology, and , , , and are students; all at the University of Washington in Seattle.

Use of local SNOMED codes and clerical errors led to the underreporting of melanomas despite having an in-house reporting system and understanding reporting requirements. Read More

View Article

Download full-text PDF

Source

Systemic Therapy in Metastatic Melanoma.

Fed Pract 2015 May;32(Suppl 4):57S-65S

is a house officer in the Department of Internal Medicine and is a professor and chief of Hematology/Oncology, both at CHI Health Creighton University Medical Center in Omaha, Nebraska. Dr. Silberstein is also the chief of oncology at VA Nebraska-Western Iowa Healthcare System in Omaha.

New targeted treatments and therapies for metastatic melanoma are improving patient prognosis and survival. Read More

View Article

Download full-text PDF

Source

Targeting intermittent hypoxia downstream pathways for biomarker discovery and new treatment perspectives in cutaneous melanoma.

Eur Respir J 2019 Feb 31;53(2). Epub 2019 Jan 31.

Université Grenoble Alpes, Inserm, CHU Grenoble Alpes, HP2, Grenoble, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1183/13993003.02444-2018DOI Listing
February 2019

Folate-directed zinc (II) phthalocyanine loaded polymeric micelles engineered to generate reactive oxygen species for efficacious photodynamic therapy of cancers.

Photodiagnosis Photodyn Ther 2019 Feb 12. Epub 2019 Feb 12.

Department of Organic and Pharmaceutical Technology, Faculty of Chemistry, Wroclaw University of Science and Technology, Wybrzeże Wyspiańskiego 27, 50-370, Wroclaw, Poland. Electronic address:

Targeted and effective drug transport is becoming an attractive option in cancer therapy since it can improve drug efficacy and reduce drugs' side effects in normal tissues. In addition to using specific surface ligand molecules, the selective drug delivery can be accomplished via enhanced permeability and retention effect. Therefore, in our studies, we entrapped zinc (II) phthalocyanine (ZnPc) - a second generation photosensitizer - in folate-functionalized micelles of the biocompatible, FDA-approved for biomedical application diblock copolymer methoxypoly(ethylene oxide)-b-poly(L-lactide) (mPEG-b-PLLA) and its derivative with folate (FA) attached to the end of PEG chain (FA-PEG-b-PLLA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pdpdt.2019.02.014DOI Listing
February 2019

Construction of saliency map and hybrid set of features for efficient segmentation and classification of skin lesion.

Microsc Res Tech 2019 Feb 15. Epub 2019 Feb 15.

Department of Information Systems, Al Yamamah University, Riyadh, KSA.

Skin cancer is being a most deadly type of cancers which have grown extensively worldwide from the last decade. For an accurate detection and classification of melanoma, several measures should be considered which include, contrast stretching, irregularity measurement, selection of most optimal features, and so forth. A poor contrast of lesion affects the segmentation accuracy and also increases classification error. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jemt.23220DOI Listing
February 2019

Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment.

J Immunother 2019 Feb 13. Epub 2019 Feb 13.

Institute of Immunobiology.

Checkpoint inhibitors have improved survival of metastatic melanoma. However, reliable biomarkers to predict response are still needed. Immunoglobulin G (IgG) antibody subclasses reflect immunocompetence in individuals and are known to be involved in essential functions in our immune system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0000000000000255DOI Listing
February 2019

Treatment in metastatic melanoma - Time to re-think.

Ann Oncol 2019 Feb 15. Epub 2019 Feb 15.

University Hospital Essen, Department of Dermatology, Essen, Germany & German Cancer Consortium, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz050DOI Listing
February 2019

Efficacy and reproducibility of lymphatics mapping technique with sentinel lymph node biopsy in melanoma.

Cir Cir 2019 ;87(2):241-246

Hospital Privado Universitario de Córdoba, Córdoba, Argentina.

Introduction: The study of the Sentinel Lymph Node (SLN) in Melanoma is a procedure that aims the identification of the first node to which the affected cutaneous sector drains in order to avoid unnecessary lymphadenectomies. The present study documents the frequency of identification of SLN; the relationship between positive SLN (PSLN) and recurrence, between the Breslow index (BI) and PSLN, and between BI and disease recurrence.

Method: We analyzed the records of 148 patients with melanoma stages I and II undergoing lymphatic mapping and GC biopsy from 1999 to 2017 in a third level institution in Córdoba, Argentina. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/CIRU.18000439DOI Listing
January 2019

Clinical features of thirty-two patients with anti-melanoma differentiation-associated gene 5 antibodies.

Clin Exp Rheumatol 2019 Feb 11. Epub 2019 Feb 11.

Department of Rheumatology and Immunology of the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Objectives: To investigate the clinical characteristics of patients positive for anti-melanoma differentiation-associated gene 5 (MDA5) antibodies, and to analyse the potential pathogenesis of anti-MDA5 antibodies.

Methods: The clinical manifestations, serological tests, imaging features, treatments, and prognoses of 32 anti-MDA5 antibody-positive patients diagnosed in the Rheumatology and Immunology Department of the Second Affiliated Hospital of Chongqing Medical University from September 2015 to August 2018 were analysed.

Results: Of the 32 anti-MDA5 antibody-positive patients, eleven patients were clinically diagnosed with interstitial pneumonia with autoimmune features (IPAF), ten patients were diagnosed with clinically amyopathic dermatomyositis (CADM), six patients were diagnosed with dermatomyositis (DM) and five patients were diagnosed with anti-synthetase syndrome (ASS). Read More

View Article

Download full-text PDF

Source
February 2019

Assessing the content and comprehensiveness of provincial and territorial indoor tanning legislation in Canada.

Health Promot Chronic Dis Prev Can 2019 Feb;39(2):45-55

Department of Population Medicine, University of Guelph, Guelph, Ontario, Canada.

Introduction: Canadian provincial and territorial governments have enacted legislation in response to health risks of artificial ultraviolet radiation from indoor tanning. This legislation, which differs from jurisdiction to jurisdiction, regulates the operation of indoor tanning facilities. The content and comprehensiveness of such legislation-and its differences across jurisdictions-have not been analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24095/hpcdp.39.2.02DOI Listing
February 2019

Viral oncolytic immunotherapy in the war on cancer: Infection control considerations.

Infect Control Hosp Epidemiol 2019 Feb 15:1-5. Epub 2019 Feb 15.

Division of Infection Control, Department of Medicine, Memorial Sloan Kettering Cancer Center,New York.

Oncolytic viral immunotherapy is an emerging treatment modality for cancer that exploits in vivo replication and other viral properties to enhance immune killing of malignant cells. The potential for horizontal transmission of native or engineered oncolytic viruses creates several unique infection control challenges. In 2015, talimogene laherparepvec (TVEC) became the first agent in this class to gain FDA approval for treatment of melanoma, and several others are being developed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/ice.2018.358DOI Listing
February 2019

Cryopreserved amniotic membrane and umbilical cord for a radiation-induced wound with exposed dura: a case report.

Authors:
David Fernandez

J Wound Care 2019 Feb;28(Sup2):S4-S8

Florida Hospital Orlando, Orlando, US.

An 87-year old male received surgical excision of scalp melanoma and subsequent radiotherapy due to metastasis to the skull. A radiation-induced wound developed with osteoradionecrosis that required necrotic bone excision resulting in a 7.5x8. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12968/jowc.2019.28.Sup2.S4DOI Listing
February 2019

Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.

Pigment Cell Melanoma Res 2019 Feb 15. Epub 2019 Feb 15.

Melanoma Institute Australia and The University of Sydney, Sydney, Australia.

Background: Brain radiotherapy is used in the management of melanoma brain metastases (MBM), and can result in radionecrosis. Anti-PD-1 is active in the brain and may increase the risk of radionecrosis when combined with radiotherapy. We studied the incidence, associated factors and management of radionecrosis in longer-term survivors with MBM treated with this combination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12775DOI Listing
February 2019

Mechanism of action of 4-substituted phenols to induce vitiligo and anti-melanoma immunity.

Pigment Cell Melanoma Res 2019 Feb 14. Epub 2019 Feb 14.

Department of Dermatology and Netherlands Institute for Pigment Disorders, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam Infection& Immunity Institute, Cancer Center Amsterdam, Amsterdam, the Netherlands.

Monobenzone is a 4-substituted phenol that can induce vitiligo and antimelanoma immunity. We investigated the influence of the chemical structure on the biological activity of a series of structurally-related 4-substituted phenols. All phenols inhibited cellular melanin synthesis, and eight of ten phenols inhibited tyrosinase activity, using the MBTH assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12774DOI Listing
February 2019

The spectrum of benign dermal dendritic melanocytic proliferations.

J Eur Acad Dermatol Venereol 2019 Feb 14. Epub 2019 Feb 14.

Professor of Pathology, Department of Pathology, Istanbul Faculty of Medicine, Istanbul University.

Dermal melanocytoses (DMs) comprise a heterogeneous group of benign lesions, located on skin and mucous membranes, characterized by dendritic melanocytes in the dermis. Although they share common histopathological features, some variants may present only as bluish or gray patches, some only as papules/nodules/plaques and others may show combination of all of these lesions. Despite the fact that blue nevus is typically characterized with papulonodular lesions, its variants may show all of the aforementioned presentations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15492DOI Listing
February 2019

Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial.

Cardiovasc Intervent Radiol 2019 Feb 14. Epub 2019 Feb 14.

Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.

Purpose: To investigate the safety and toxicity of percutaneous hepatic perfusion with melphalan (M-PHP) with the Delcath Systems' second-generation (GEN 2) filter and compare the outcomes with historical data from studies using the first-generation filter.

Materials And Methods: A prospective, single-arm, single-center phase II study was carried out including 35 patients with unresectable, histologically confirmed liver metastases from ocular melanoma between February 2014 and June 2017. Main exclusion criteria were extrahepatic disease and age > 75 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00270-019-02177-xDOI Listing
February 2019

Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine.

Support Care Cancer 2019 Feb 14. Epub 2019 Feb 14.

Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.

The most common adverse event (AE) of dabrafenib and trametinib (DT) is pyrexia, which has been reported to occur in up to 71% of patients. Pyrexia resulted in therapy discontinuation in up to 26% of patients that otherwise were benefiting from the treatment. Little is known about the pathogenesis and optimal management of this common AE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-019-4654-2DOI Listing
February 2019

Mucosal melanoma of the head-and-neck region: A single institutional clinical experience.

South Asian J Cancer 2019 Jan-Mar;8(1):26

Department of Radiotherapy, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/sajc.sajc_326_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348772PMC
February 2019

A PDZ Protein MDA-9/Syntenin: As a Target for Cancer Therapy.

Comput Struct Biotechnol J 2019 8;17:136-141. Epub 2019 Jan 8.

Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, PR China.

Melanoma differentiation-associated gene 9 (MDA-9)/Syntenin is a multidomain PDZ protein and identified as a key oncogene in melanoma initially. This protein contains a unique tandem PDZ domain architecture (PDZ1 and PDZ2 spaced by a 4-amino acid linker), an N-terminal domain (NTD) that is structurally uncharacterized and a short C-terminal domain (CTD). The PDZ1 domain is regarded as the PDZ signaling domain while PDZ2 served as the PDZ superfamily domain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.csbj.2019.01.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360254PMC
January 2019

Mediators of Inflammation in Topical Therapy of Skin Cancers.

Mediators Inflamm 2019 10;2019:8369690. Epub 2019 Jan 10.

Carol Davila University of Medicine and Pharmacy Bucharest, Romania, Bucharest, Romania.

Taking into consideration that the immune system plays a very important role in the development of melanoma and non-melanoma skin cancers, which have a high prevalence in immunosuppressed patients and after prolonged ultraviolet radiation, the interest in developing novel therapies, in particular targeting the inflammation in cancer, has increased in the past years. The latest data suggest that therapies such as imiquimod (IMQ), ingenol mebutate (IM), 5-fluorouracil (5-FU), retinoids, and nonsteroidal anti-inflammatory drugs (NSAIDs) have been used with success in the topical treatment of some cancers. Herein, we review the topical treatment targeting the inflammation in skin cancer and the mechanisms involved in these processes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/8369690DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350587PMC
January 2019

Using Dermoscopy to Identify Melanoma and Improve Diagnostic Discrimination.

Fed Pract 2018 May;35(Suppl 4):S39-S45

is a Medical Student at the University of California, Riverside in Riverside, California. is a Medical Student, is a PGY-2 Dermatology Resident, and is a PGY-4 Dermatology Resident, all at Loma Linda University in Loma Linda, California. is the Dermatology Section Chief and Professor of Dermatology, and is the Dermatology Clinical Director and Assistant Professor of Dermatology, both at Loma Linda University and the Loma Linda VA Medical Center.

Use of dermoscopy and detection algorithms by primary care physicians can enhance assessment of clinically suspicious lesions compared with that of naked eye examinations. Read More

View Article

Download full-text PDF

Source

Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant.

J Am Soc Nephrol 2019 Feb 14. Epub 2019 Feb 14.

School of Public Health, University of Sydney, Sydney, Australia.

Patients with ESRD have a substantially increased cancer risk, but few studies have examined the patterns of cancer mortality along a patient's journey from dialysis to transplantation.

Methods: We identified all Australian patients on dialysis and patients with transplants from 1980 to 2014 from the Australia and New Zealand Dialysis and Transplant Registry. Using standardized mortality ratios (SMRs), we compared cancer mortality among patients on dialysis and patients with transplants versus the general population (overall and by age, sex, year, and site); we also performed a subgroup analysis excluding patients with preexisting cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1681/ASN.2018090906DOI Listing
February 2019
9.343 Impact Factor

BRAF targeting sensitizes resistant melanoma to cytotoxic T cells.

Clin Cancer Res 2019 Feb 14. Epub 2019 Feb 14.

Translational Tumor Immunology, Wistar Institute

Purpose: BRAF and MEK inhibitors (BRAFi, MEKi) are actively used for the treatment of metastatic melanoma in patients with BRAF mutation in their tumors. However, the development of resistance to BRAFi and MEKi remains a difficult clinical challenge with limited therapeutic options available to these patients. In this study we investigated the mechanism and potential therapeutic utility of combination BRAFi and adoptive T cells therapy (ACT) in melanoma resistant to BRAFi. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-2725DOI Listing
February 2019

Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma.

Eur J Surg Oncol 2019 Feb 5. Epub 2019 Feb 5.

Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, PO Box 1738, 3000 DR, Rotterdam, The Netherlands; Institute for Medical Technology Assessment, Erasmus University Rotterdam, PO Box 1738, 3000 DR, Rotterdam, The Netherlands.

Objective: To investigate stage-specific survival from diagnosis, stage-specific disease recurrence, and post-recurrence survival in patients diagnosed with localized and regionally advanced cutaneous melanoma.

Methods: A retrospective, observational cohort study was conducted in six Dutch hospitals. We included patients with a first diagnosis of stage I, II, or III melanoma between January 2003 and December 2011. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejso.2019.01.225DOI Listing
February 2019

Retrospective single-center study evaluating clinical and dermoscopic features of longitudinal melanonychia, ABCDEF criteria, and risk of malignancy.

J Am Acad Dermatol 2019 Feb 11. Epub 2019 Feb 11.

Department of Dermatology, Weill Cornell Medicine, New York, New York. Electronic address:

Background: Longitudinal melanonychia (LM) is a common finding in clinical practice; however, it has a broad differential diagnosis, including subungual melanoma (SUM), which can be difficult to distinguish clinically from benign conditions.

Objective: To identify clinical and dermoscopic features that distinguish histopathologically diagnosed SUM from benign LM and to evaluate the validity of the ABCDEF criteria among patients on whom a biopsy was performed.

Methods: Retrospective cohort study of consecutive patients who underwent nail matrix biopsy for LM at a single center from January 2011 to November 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.08.033DOI Listing
February 2019

Corrigendum to "Exosomes derived from TRAIL-engineered mesenchymal stem cells with effective anti-tumor activity in a mouse melanoma model" [International Journal of Pharmaceutics 549 (2018) 218-229].

Int J Pharm 2019 Mar;558:441

Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:

Exosomes are biological nano-sized vesicles (~30-200 nm in diameter) that are produced by a wide range of cells and play several roles in cell-cell communications. These vesicles contain membrane and cytoplasmic components of producing cells. Mesenchymal stem cells (MSCs) are the ideal producer of exosomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijpharm.2019.02.003DOI Listing

Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth.

J Exp Clin Cancer Res 2019 Feb 14;38(1):78. Epub 2019 Feb 14.

Takis, Rome, Italy.

Background: Personalized cancer vaccines based on neoantigens have reached the clinical trial stage in melanoma. Different vaccination protocols showed efficacy in preclinical models without a clear indication of the quality and the number of neoantigens required for an effective cancer vaccine.

Methods: In an effort to develop potent and efficacious neoantigen-based vaccines, we have developed different neoantigen minigene (NAM) vaccine vectors to determine the rules for a successful neoantigen cancer vaccine (NCV) delivered by plasmid DNA and electroporation. Read More

View Article

Download full-text PDF

Source
https://jeccr.biomedcentral.com/articles/10.1186/s13046-019-
Publisher Site
http://dx.doi.org/10.1186/s13046-019-1084-4DOI Listing
February 2019
2 Reads

The great escape: How metastases of melanoma, and other carcinomas, avoid elimination.

Exp Biol Med (Maywood) 2018 Dec 6;243(17-18):1245-1255. Epub 2019 Jan 6.

6 Department of Surgery, Allegheny Health Network, Pittsburgh, PA 15224, USA.

Impact Statement: Cancers kill mainly because metastatic disease is resistant to systemic therapies. It was hoped that newer targeted and immunomodulatory interventions could overcome these issues. However, recent findings point to a generalized resistance to elimination imparted by both cancer-intrinsic and -extrinsic changes to provide survival advantages to the disseminated tumor cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1535370218820287DOI Listing
December 2018

Primary malignant melanoma of the vagina, case report and review of the literature.

Ceska Gynekol 2018 ;83(3):201-199

Objective: Presentation of primary malignant melanoma of the vagina. Summary of clinical findings and management.

Design: Case report. Read More

View Article

Download full-text PDF

Source
January 2018

Activation of CD8⁺ T Cell Responses after Melanoma Antigen Targeting to CD169⁺ Antigen Presenting Cells in Mice and Humans.

Cancers (Basel) 2019 Feb 5;11(2). Epub 2019 Feb 5.

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Infection and Immunity Institute, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands.

The lack of tumor-reactive T cells is one reason why immune checkpoint inhibitor therapies still fail in a significant proportion of melanoma patients. A vaccination that induces melanoma-specific T cells could potentially enhance the efficacy of immune checkpoint inhibitors. Here, we describe a vaccination strategy in which melanoma antigens are targeted to mouse and human CD169 and thereby induce strong melanoma antigen-specific T cell responses. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/2072-6694/11/2/183
Publisher Site
http://dx.doi.org/10.3390/cancers11020183DOI Listing
February 2019
1 Read

Pneumatosis intestinalis after molecular targeted therapy.

World Neurosurg 2019 Feb 11. Epub 2019 Feb 11.

Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address:

Background: Pneumoperitoneum after surgical manipulation of the abdomen implies a perforation. Rare cases of non-operated cancer patients, largely with gastrointestinal or genitourinary cancers, have been noted to have radiological findings of pneumatosis intestinalis and/or pneumoperitoneum as a complication of molecular-targeted therapy (MTT) without confounding factors for perforation. We present a patient with a cranial malignancy treated with bevacizumab who subsequently manifested with pneumatosis intestinalis. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18788750193033
Publisher Site
http://dx.doi.org/10.1016/j.wneu.2019.01.225DOI Listing
February 2019
1 Read

Long-Term Survival after Brain and Spine Metastasis in Malignant Melanoma.

World Neurosurg 2019 Feb 11. Epub 2019 Feb 11.

Ohio State University Wexner Medical Center and Arthur G. James Cancer Hospital, Columbus, OH.

Background: Metastasis from melanoma carries poor prognosis and survival. Average life expectancy is estimated four to six months following diagnosis of skeletal metastasis. Comprehensive treatment, along with newer immunotherapies, has shown promising results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2019.01.215DOI Listing
February 2019

Corneal Substructure Dosimetry Predicts Corneal Toxicity in Patients with Uveal Melanoma Treated with Proton Beam Therapy.

Int J Radiat Oncol Biol Phys 2019 Feb 11. Epub 2019 Feb 11.

Department of Radiation Oncology, University of Washington School of Medicine, Seattle, WA 98195, USA.

Purpose: The present study examines the relationship between dose to corneal substructures and incidence of corneal toxicity within six months of proton beam therapy (PBT) for uveal melanoma. We aim to develop clinically meaningful dose constraints that can be used to mitigate corneal toxicity.

Methods And Materials: Ninety-two patients were treated with PBT between 2015 and 2017 and evaluated for grade 2+ (GR2+), intervention-requiring corneal toxicity in our prospectively maintained database. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03603016193019
Publisher Site
http://dx.doi.org/10.1016/j.ijrobp.2019.02.005DOI Listing
February 2019
1 Read
4.258 Impact Factor

Evaluation of A Novel Pb-203-Labeled Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptide for Melanoma Targeting.

Mol Pharm 2019 Feb 14. Epub 2019 Feb 14.

The purpose of this study is to examine the melanocortin-1 receptor (MC1R) targeting and specificity of 203Pb-DOTA-GGNle-CycMSHhex in melanoma cells and tumors to facilitate its potential therapeutic application when labeled with 212Pb. The melanocortin-1 receptor (MC1R)-specific targeting and imaging properties of 203Pb-DOTA-GGNle-CycMSHhex were determined on B16/F1 and B16/F10 murine melanoma cells, and in B16/F1 flank melanoma-, B16/F10 flank melanoma- and B16/F10 pulmonary metastatic melanoma-bearing C57 mice. 203Pb-DOTA-GGNle-CycMSHhex displayed MC1R-specific binding on B16/F1 and B16/F10 melanoma cells and tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.molpharmaceut.9b00025DOI Listing
February 2019